Lacosamide vs Carbamazepine: Mechanism and Refractory Period Effects
Lacosamide and carbamazepine both block voltage-gated sodium channels but through fundamentally different mechanisms: lacosamide selectively enhances slow inactivation without affecting fast inactivation, while carbamazepine primarily blocks fast-inactivated states—this mechanistic difference translates to lacosamide prolonging the absolute refractory period through slow inactivation enhancement, whereas carbamazepine works during the relative refractory period through fast inactivation.
Key Mechanistic Differences
Carbamazepine's Mechanism
- Acts on fast inactivation: Reduces polysynaptic responses and blocks post-tetanic potentiation 1
- Binds to fast-inactivated states: Shifts steady-state fast inactivation curves in the hyperpolarizing direction 2
- Time scale: Works within milliseconds to seconds
- Recovery: Block is removed rapidly (within 500ms) upon hyperpolarization to -100mV 2
Lacosamide's Unique Profile
- Selectively enhances slow inactivation: The only ASM in clinical practice with this predominant mechanism 3
- Does NOT affect fast inactivation: No shift in fast inactivation curves, no effect on sustained repetitive firing on millisecond time scales 3, 2
- Time scale: Terminates sustained repetitive firing over seconds, not milliseconds 3
- Persistent block: Unlike carbamazepine, lacosamide's block is NOT removed by hyperpolarization to -100mV 2
- Voltage-dependent: Shifts slow inactivation curve to more hyperpolarized potentials and enhances maximal fraction of channels in slow inactivated state 3
Effects on Refractory Periods
Absolute Refractory Period
Lacosamide directly prolongs the absolute refractory period by enhancing slow inactivation, which keeps sodium channels unavailable for longer durations even after membrane repolarization 2. This is mechanistically distinct from traditional sodium channel blockers.
Relative Refractory Period
Carbamazepine primarily affects the relative refractory period by stabilizing fast-inactivated states, making it harder to generate action potentials during partial recovery 1, 2.
Clinical Implications
Efficacy Considerations
- Both are effective for focal seizures: Lacosamide demonstrated non-inferiority to controlled-release carbamazepine 4
- Seizure selectivity: Lacosamide's slow inactivation mechanism may be relatively selective for repeatedly depolarized neurons participating in seizure activity 5
- Refractory epilepsy: Both can be used, though guidelines from 2004 predate lacosamide approval 6
Safety and Tolerability Profile
Carbamazepine adverse effects 1:
- Enzyme inducer (CYP3A4)
- Autoinduction over 3-5 weeks
- Multiple drug interactions
- Elevated liver enzymes (GGT)
- Idiosyncratic reactions more common
- NOT an enzyme inducer
- Better tolerability profile
- Switching from carbamazepine to lacosamide significantly reduces GGT levels (median 141.5 to 63.5 IU/L) 4
- Can be switched abruptly without cross-titration in controlled patients 4
Critical Therapeutic Drug Monitoring Caveat
The updated lacosamide reference range of 10-20 mg/L clearly increases toxicity 7. At trough levels >10 mg/L, 41% of patients reported adverse effects. Target trough levels should be adjusted to ≤12 mg/L to balance efficacy and minimize toxicity 7.
Practical Algorithm for Drug Selection
Choose lacosamide over carbamazepine when:
- Patient has elevated liver enzymes on carbamazepine
- Multiple drug-drug interactions are a concern
- Patient is on enzyme-sensitive medications
- Better tolerability is needed
Choose carbamazepine when:
- Cost is a primary concern
- Long-term safety data is prioritized
- Patient has well-controlled seizures on current regimen
Common pitfall: Do not assume the 10-20 mg/L reference range for lacosamide is safe—this range was derived from peak levels, not trough levels, and causes significant toxicity in clinical practice 7.